Development of a new biomedical implant based on optogenetics technology – the combination of genetics and optics techniques to control and monitor activities of cells in a living tissue with light to activate cells to produce themselves the necessary drug (interferon-ß (IFN-ß) protein in this case) – that can be applied to improve the treatment of Multiple Sclerosis ,improve the quality of life of people affected by this disease and reduce the side effects of current treatments.
Optogenerapy project t is led by Eurecat and counts on the participation of eleven partners from seven different European countries. This project has received funding from the European Union’s Horizon 2020 research and innovation programme.
Optogenerapy – Optogenetic Protein Therapy for Multiple Sclerosis
Programme and call for tender
Project funded by the European Union’s Horizon 2020 programme under the call ICT-21-2016 “Support technology transfer to the creative industries”.